Search Results

Pearl Bio today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.

Synthetic biology company Pearl Bio announced Tuesday it has entered into a license and collaboration agreement with Merck to discover biologic therapies comprising non-standard amino acids.

Pearl Bio , a synthetic biology company backed by Khosla Ventures, is recoding life to create a new era of biologics and biomaterials.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation.

Pearl Huang, Ph.D, has been appointed the CEO of U.K.-based Dunad Therapeutics, a Novartis-backed biopharmaceutical startup.

Data presented at the European Academy of Neurology Congress 2023 Teva Pharmaceutical Industries Ltd. announces further positive data from the pan-European PEARL study investigating the impact of AJOVY® on the prevention of migraine in a real-world setting,1 due to be completed in 2024.

Maggie’s Pearl, a joint venture between Perlara, Maggie’s Cure, and the Mayo Clinic, has started a Phase III clinical treatment trial to evaluate safety, tolerability, and clinical and metabolic improvement of pediatric subjects with PMM2-CDG (formerly known as Congenital Disorder of Glycosylation Type 1a) on oral epalrestat therapy versus a placebo.

Pearl Health, a leading technology company focused on physician enablement and risk bearing in value-based care, today announced that it has raised $75 million in its oversubscribed Series B funding round, led by Andreessen Horowitz’s Growth Fund and Viking Global Investors, with participation by AlleyCorp, SV Angel’s Growth Fund, and other leading investors.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) mandated or recommended by some reimbursement authorities after one year of continuous use.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system